Total Payments
$2,178
2024 Payments
$334.39
Companies
25
Transactions
112
Medicare Patients
2,262
Medicare Billing
$585,521
Payment Breakdown by Category
Food & Beverage$2,125 (97.6%)
Education$52.61 (2.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,125 | 106 | 97.6% |
| Education | $52.61 | 6 | 2.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $323.61 | 14 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $265.11 | 13 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $188.67 | 10 | $0 (2023) |
| Vifor Pharma, Inc. | $169.69 | 8 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $143.41 | 7 | $0 (2024) |
| Baxter Healthcare | $125.00 | 1 | $0 (2024) |
| Lundbeck LLC | $106.09 | 6 | $0 (2019) |
| Relypsa, Inc. | $94.39 | 6 | $0 (2020) |
| Alexion Pharmaceuticals, Inc. | $85.99 | 5 | $0 (2024) |
| Daiichi Sankyo Inc. | $81.31 | 5 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $334.39 | 13 | Baxter Healthcare ($125.00) |
| 2023 | $283.79 | 13 | Vifor Pharma, Inc. ($95.57) |
| 2022 | $327.36 | 15 | Amgen Inc. ($73.05) |
| 2021 | $112.30 | 7 | Bayer HealthCare Pharmaceuticals Inc. ($35.62) |
| 2020 | $81.69 | 5 | AstraZeneca Pharmaceuticals LP ($29.62) |
| 2019 | $295.65 | 16 | Amgen Inc. ($55.40) |
| 2018 | $351.17 | 21 | Lundbeck LLC ($83.86) |
| 2017 | $391.37 | 22 | Otsuka America Pharmaceutical, Inc. ($82.45) |
All Payment Transactions
112 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/04/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $18.73 | General |
| Category: Rare Disease | ||||||
| 11/18/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $19.82 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/12/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $20.25 | General |
| 11/11/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $23.97 | General |
| Category: Immunology | ||||||
| 10/08/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $19.82 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 09/26/2024 | Baxter Healthcare | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 09/25/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $17.84 | General |
| Category: Cardiology | ||||||
| 05/29/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $21.69 | General |
| Category: Cardio-renal | ||||||
| 04/25/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $3.08 | General |
| 04/22/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $16.89 | General |
| 04/22/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $3.08 | General |
| 03/04/2024 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $20.54 | General |
| Category: Hyperkalemia | ||||||
| 02/12/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $23.68 | General |
| Category: Inflammation | ||||||
| 10/27/2023 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $20.16 | General |
| Category: CRITICAL CARE | ||||||
| 10/11/2023 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $24.06 | General |
| Category: Hyperkalemia | ||||||
| 10/06/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $22.59 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/11/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $17.96 | General |
| Category: Cardio-renal | ||||||
| 06/21/2023 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $25.08 | General |
| Category: Hyperkalemia | ||||||
| 05/22/2023 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $26.92 | General |
| Category: NEPHROLOGY | ||||||
| 05/15/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $18.03 | General |
| Category: Cardio-renal | ||||||
| 05/12/2023 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $26.25 | General |
| Category: Hyperkalemia | ||||||
| 05/11/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $19.93 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/07/2023 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $15.52 | General |
| Category: IMMUNOLOGY | ||||||
| 02/06/2023 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $20.18 | General |
| Category: Hyperkalemia | ||||||
| 01/25/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $23.67 | General |
| Category: Cardiovascular and Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 273 | 548 | $179,153 | $69,402 |
| 2022 | 10 | 288 | 715 | $237,807 | $94,604 |
| 2021 | 13 | 541 | 1,209 | $421,844 | $167,657 |
| 2020 | 18 | 1,160 | 4,016 | $725,221 | $253,859 |
Total Patients
2,262
Total Services
6,488
Medicare Billing
$585,521
Procedure Codes
50
All Medicare Procedures & Services
50 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 21 | 129 | $76,239 | $34,795 | 45.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 52 | 109 | $16,459 | $6,664 | 40.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 50 | 81 | $18,306 | $6,111 | 33.4% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 53 | 93 | $23,808 | $5,186 | 21.8% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 11 | 19 | $9,329 | $4,352 | 46.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 24 | 40 | $12,040 | $4,231 | 35.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 24 | 25 | $9,900 | $3,160 | 31.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 17 | 31 | $6,541 | $2,878 | 44.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 21 | 21 | $6,531 | $2,025 | 31.0% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 33 | 203 | $119,973 | $54,979 | 45.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 55 | 161 | $24,311 | $8,502 | 35.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 48 | 73 | $16,498 | $6,380 | 38.7% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 47 | 106 | $27,136 | $5,716 | 21.1% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 12 | 20 | $9,820 | $4,407 | 44.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 19 | 28 | $8,428 | $3,887 | 46.1% |
| 90945 | Dialysis procedure including 1 evaluation | Facility | 2022 | 14 | 47 | $9,494 | $3,114 | 32.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 20 | 20 | $7,920 | $2,835 | 35.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 19 | 35 | $7,385 | $2,629 | 35.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 21 | 22 | $6,842 | $2,155 | 31.5% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 51 | 289 | $170,764 | $78,176 | 45.8% |
| 90966 | Home dialysis services per month, patient 20 years of age or older | Office | 2021 | 13 | 110 | $59,499 | $24,226 | 40.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 72 | 212 | $31,967 | $11,736 | 36.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 113 | 141 | $31,792 | $11,211 | 35.3% |
| 90935 | Hemodialysis procedure with one physician evaluation | Facility | 2021 | 64 | 157 | $40,171 | $8,897 | 22.1% |
| 90961 | Dialysis services (2-3 physician visits per month), patient 20 years of age and older | Office | 2021 | 24 | 39 | $19,139 | $8,874 | 46.4% |
About Dr. Lance Dicker, MD
Dr. Lance Dicker, MD is a Nephrology healthcare provider based in Salem, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/18/2007. The National Provider Identifier (NPI) number assigned to this provider is 1902022817.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lance Dicker, MD has received a total of $2,178 in payments from pharmaceutical and medical device companies, with $334.39 received in 2024. These payments were reported across 112 transactions from 25 companies. The most common payment nature is "Food and Beverage" ($2,125).
As a Medicare-enrolled provider, Dicker has provided services to 2,262 Medicare beneficiaries, totaling 6,488 services with total Medicare billing of $585,521. Data is available for 4 years (2020–2023), covering 50 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Salem, OR
- Active Since 04/18/2007
- Last Updated 07/08/2007
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1902022817
Products in Payments
- Veltassa (Drug) $236.88
- Parsabiv (Biological) $164.88
- Kerendia (Drug) $143.41
- FARXIGA (Drug) $142.56
- JYNARQUE (Drug) $123.57
- LOKELMA (Drug) $122.55
- NORTHERA (Drug) $106.09
- SAMSCA (Drug) $94.29
- INJECTAFER (Drug) $81.31
- Rituxan (Biological) $79.66
- KRYSTEXXA (Biological) $75.22
- Parsabiv (Drug) $71.86
- SOLIRIS (Drug) $67.26
- Auryxia (Drug) $57.49
- KRYSTEXXA (Drug) $56.83
- Velphoro (Drug) $50.59
- TAVNEOS (Drug) $47.91
- BENLYSTA (Biological) $39.40
- ENTRESTO (Drug) $24.22
- Fabhalta (Drug) $23.97
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Salem
Dr. Ana Stankovic, Md Facp Fasn Fash, MD FACP FASN FASH
Nephrology — Payments: $396,936
Nephrology $396,936
Csaba Kovesdy, M.d, M.D
Nephrology — Payments: $208,661
Nephrology $208,661
Brett Mikeska, M D, M D
Nephrology — Payments: $655.03
Nephrology $655.03
Denis Privalov, Md, MD
Nephrology — Payments: $620.47
Nephrology $620.47
Eva Lee, M D, M D
Nephrology — Payments: $510.22
Nephrology $510.22
Devasmita Dev, M. D, M. D
Nephrology — Payments: $414.04
Nephrology $414.04